Saponin and Ribosome-Inactivating Protein Synergistically Trigger Lysosome-Dependent Apoptosis by Inhibiting

Piao Chen1, Xue-Wei Cao1,2,3, Jing-Wen Dong2,3

  • 1Department of Applied Biology, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, People's Republic of China.

PubMed

Insights

QS-21 and MAP30 synergistically induce tumor cell death by disrupting lysosomal membranes and inhibiting lysophagy, offering a novel therapeutic strategy for cancer treatment.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Lysosomal membrane permeabilization (LMP) by cationic amphiphilic drugs (CADs) can trigger lysosome-dependent cell death (LDCD) for cancer therapy.
  • Intrinsic cellular mechanisms that repair lysosomal damage limit the efficacy of CADs.

Purpose of the Study:

  • To investigate the synergistic effect of QS-21 and MAP30 on tumor cell apoptosis.
  • To elucidate the mechanism by which QS-21 and MAP30 induce LDCD.

Main Methods:

  • Treatment of tumor cells with varying concentrations of QS-21 and MAP30.
  • Analysis of lysosomal membrane integrity, cathepsin leakage, and autophagy markers (LC3).
  • Assessment of apoptosis and cell death induction.

Main Results:

  • Low concentrations of QS-21 induced LMP without toxicity to tumor cells.
  • QS-21 and MAP30 exhibited synergistic apoptosis induction in tumor cells.
  • QS-21 facilitated MAP30 entry into the endoplasmic reticulum by promoting LMP, inhibiting lysophagy, and leading to cathepsin leakage and LDCD.

Conclusions:

  • Coadministration of QS-21 and MAP30 enhances lysosomal disruption and triggers synergistic LDCD.
  • This combination represents a promising new strategy for synergistic LDCD-based antitumor therapy.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K